1628730-49-3
Chemical Structure
Praliciguat
Synonym(s): IW-1973
- CAS No.: 1628730-49-3
- Formula:C21H14F8N6O2
- Molecular Weight:534.36
IUPAC Name: 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol
InChIKey: CYSJNTQNMDWAJV-UHFFFAOYSA-N
SMILES: FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NCC(C(F)(F)F)(O)C(F)(F)F)=N4)=N2
Biological Activity: Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Praliciguat | 99.35% | Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Praliciguat (Standard) | ≥98% | Praliciguat (Standard) is the analytical standard of Praliciguat (HY-109039). This product is intended for research and analytical applications. Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytoKines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.86
HY-109066Olinciguat -
Similarity Score 0.64
HY-117443IWP-051 -
Similarity Score 0.48
HY-16774RVericiguat (Standard) -
Similarity Score 0.46
HY-78237Nelociguat -
Similarity Score 0.46
HY-12376BAY 41-2272 -
Similarity Score 0.46
HY-14779S3Riociguat-d3 -
Similarity Score 0.46
HY-14779Riociguat -
Similarity Score 0.45
HY-187209SGC stimulator 2 -
Similarity Score 0.45
HY-142697SGC agonist 1 -
Explore the MedChemAI to find more analogs
References
- [1]. Daniel P Zimmer, et al. Abstract 16938: IW-1973 is a Potent Soluble Guanylate Cyclase Stimulator in vitro and in vivo With Extensive Tissue Distribution.
- [2]. Liu G, et al. Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F697-F711. [Content Brief]
- [3]. Shea CM, et al. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F148-F159. [Content Brief]
